Adhera Therapeutics (ATRX) 10-Q 21 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 18, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-13789
Entity Registrant Name	ADHERA THERAPEUTICS, INC.
Entity Central Index Key	0000737207
Entity Tax Identification Number	11-2658569
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8000 Innovation Parkway
Entity Address, City or Town	Baton Rouge
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70820
City Area Code	(919)
Local Phone Number	518-3748
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,223,505

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash	$ 58,000	$ 32,000
Prepaid expenses	24,000	47,000
Total current assets	82,000	79,000
Total assets	82,000	79,000
Current liabilities
Accounts payable	2,318,000	2,397,000
Due to related parties	16,000	26,000
Accrued expenses	5,139,000	4,373,000
Accrued dividends	551,000	498,000
Term loans, net of discounts	9,415,000	7,333,000
Convertible notes payable	1,176,000	1,252,000
Derivative liability	4,254,000	6,386,000
Total current liabilities	22,869,000	22,265,000
Total liabilities	22,869,000	22,265,000
Commitments and contingencies (Note 9)
Stockholders’ deficit
Preferred stock, value
Common stock, $0.006 par value; 180,000,000 shares authorized, 3,839,454 and 3,160,877 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	23,000	19,000
Additional paid-in capital	33,610,000	33,548,000
Accumulated deficit	(56,418,000)	(55,751,000)
Treasury Stock (5,594 shares)	(2,000)	(2,000)
Total stockholders’ deficit	(22,787,000)	(22,186,000)
Total liabilities and stockholders’ deficit	82,000	79,000
Series C Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock, value
Series D Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock, value
Series E Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock, value
Series F Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock, value
Series G Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock, value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	100,000	100,000
Common stock, par value	$ 0.006	$ 0.006
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	3,839,454	3,160,877
Common stock, shares outstanding	3,839,454	3,160,877
Treasury stock, shares	5,594	5,594
Series C convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	1,200	1,200
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Preferred stock, liquidation preference value	$ 510,000	$ 510,000
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	220	220
Preferred stock, shares issued	40	40
Preferred stock, shares outstanding	40	40
Preferred stock, liquidation preference value	$ 12,000	$ 12,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	3,500	3,500
Preferred stock, shares issued	267	267
Preferred stock, shares outstanding	267	267
Series F Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	2,200	2,200
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	6,000	6,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses
General and administrative	$ 296	$ 449	$ 648	$ 709
Total operating expenses	296	449	648	709
Loss from operations	(296)	(449)	(648)	(709)
Other income (expense)
Interest expense, net	(357)	(361)	(692)	(672)
Initial and change in the fair value of derivative liability	1,742	1,012	2,459	1,679
Loan inducement expense	(462)		(809)
Gain on extiguishment of debt	36	210	75	215
Amortization of debt discount	(392)	(313)	(1,000)	(488)
Total other income (expense)	567	548	33	734
Net income (loss)	271	99	(615)	25
Accrued dividends	(26)	(406)	(53)	(566)
Net Income (Loss) Applicable to Common Stockholders	$ 245	$ (307)	$ (668)	$ (541)
Net loss per share – Common Stockholders -  basic	$ 0.07	$ (0.27)	$ (0.20)	$ (0.27)
Weighted average shares outstanding - basic	3,462,539	1,140,083	3,260,540	2,003,921
Net  loss per share – Common Stockholders -  diluted	$ (0.01)	$ (0.27)	$ (0.20)	$ (0.27)
Weighted average shares outstanding - diluted	98,538,396	1,140,083	3,260,540	2,003,921

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series E Preferred Stock [Member]	Preferred Stock [Member] Series F Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Beginning balance at Dec. 31, 2021					$ 5	$ 27,906	$ (53,017)		$ (25,106)
Beginning balance, shares at Dec. 31, 2021	100	40	3,326	358	853,946
Accrued dividends							(364)		(364)
Issuance of common stock with convertible notes						18			18
Issuance of common stock with convertible notes, shares					12,500
Issuance of Common stock for convertible note conversions						28			28
Issuance of common stock for convertible note conversions, shares					12,721
Net Loss							(74)		(74)
Ending balance at Mar. 31, 2022					$ 5	27,952	(53,455)		(25,498)
Ending balance, shares at Mar. 31, 2022	100	40	3,326	358	879,167
Beginning balance at Dec. 31, 2021					$ 5	27,906	(53,017)		(25,106)
Beginning balance, shares at Dec. 31, 2021	100	40	3,326	358	853,946
Net Loss									25
Ending balance at Jun. 30, 2022					$ 18	33,547	(53,558)	(2)	(19,995)
Ending balance, shares at Jun. 30, 2022	100	40	267		3,160,877
Beginning balance at Mar. 31, 2022					$ 5	27,952	(53,455)		(25,498)
Beginning balance, shares at Mar. 31, 2022	100	40	3,326	358	879,167
Accrued dividends							(202)		(202)
Net Loss							99		99
Issuance of common stock with term loan						11			11
Issuance of common stock with term loan, shares					19,231
Conversion of Series E Preferred to common stock					$ 12	5,044			5,056
Conversion of Series E Preferred to common stock, shares			(3,059)		2,035,306
Conversion of Series F Preferred to common stock					$ 1	540			541
Conversion of Series F Preferred to common stock, shares				(358)	233,127
Repurchase of common stock								(2)	(2)
Repurchase of common stock, shares					(5,954)
Ending balance at Jun. 30, 2022					$ 18	33,547	(53,558)	(2)	(19,995)
Ending balance, shares at Jun. 30, 2022	100	40	267		3,160,877
Beginning balance at Dec. 31, 2022					$ 19	33,548	(55,751)	(2)	(22,186)
Beginning balance, shares at Dec. 31, 2022	100	40	267		3,160,877
Accrued dividends							(26)		(26)
Issuance of Common stock for convertible note conversions						5			5
Issuance of common stock for convertible note conversions, shares					17,861
Net Loss							(886)		(886)
Ending balance at Mar. 31, 2023					$ 19	33,553	(56,663)	(2)	(23,093)
Ending balance, shares at Mar. 31, 2023	100	40	267		3,178,738
Beginning balance at Dec. 31, 2022					$ 19	33,548	(55,751)	(2)	$ (22,186)
Beginning balance, shares at Dec. 31, 2022	100	40	267		3,160,877
Issuance of common stock for convertible note conversions, shares									12,487,902
Net Loss									$ (615)
Ending balance at Jun. 30, 2023					$ 23	33,610	(56,418)	(2)	(22,787)
Ending balance, shares at Jun. 30, 2023	100	40	267		3,839,454
Beginning balance at Mar. 31, 2023					$ 19	33,553	(56,663)	(2)	(23,093)
Beginning balance, shares at Mar. 31, 2023	100	40	267		3,178,738
Accrued dividends							(26)		(26)
Issuance of Common stock for convertible note conversions					$ 4	57			61
Issuance of common stock for convertible note conversions, shares					660,716
Net Loss							271		271
Ending balance at Jun. 30, 2023					$ 23	$ 33,610	$ (56,418)	$ (2)	$ (22,787)
Ending balance, shares at Jun. 30, 2023	100	40	267		3,839,454

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Cash Flows Used in Operating Activities:
Net income (loss)	$ 271,000	$ (886,000)	$ 99,000	$ (74,000)	$ (615,000)	$ 25,000
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and fees					1,000,000	488,000
Accrued interest expense	357,000		361,000		692,000	672,000
Derivative (income) expense					(2,459,000)	(1,679,000)
Loan inducement fee	462,000				809,000
Gain on debt extinguishment	(36,000)		(210,000)		(75,000)	(215,000)
Changes in operating assets and liabilities:
Prepaid expenses					23,000	(7,000)
Accounts payable					(89,000)	30,000
Accrued expenses					88,000	(4,000)
Net Cash Used in Operating Activities					(626,000)	(690,000)
Cash Flows Provided by Financing Activities:
Proceeds from notes payable, net of original issue discounts					805,000	2,200,000
Notes payable issuance costs					(58,000)	(328,000)
Repurchase of common stock						(2,000)
Repayment of principal and interest on notes payable					(95,000)	(407,000)
Net Cash Provided by Financing Activities					652,000	1,463,000
Net increase (decrease) in cash					26,000	773,000
Cash – Beginning of Period		$ 32,000		$ 76,000	32,000	76,000	$ 76,000
Cash - End of Period	$ 58,000		$ 849,000		58,000	849,000	$ 32,000
Supplementary Cash Flow Information:
Cash paid for interest					4,000	81,000
Cash paid for taxes
Non-cash Investing and Financing Activities:
Conversion of Series E Preferred stock to Common stock						5,056,000
Conversion of Serie F Preferred stock to Common stock						541,000
Debt discounts for issuance costs, warrants and derivatives					407,000	10,000
Issuance of common stock for conversion of convertible notes					4,000	28,000
Issuance of common stock with convertible notes						20,000
Accrued dividends					$ 53,000	$ 566,000

Organization and Business Opera

Organization and Business Operations	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	Note 1 – Organization and Business Operations Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” we or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is focused on drug development and commercialization of “small molecule” drugs to treat Parkinson’s disease (PD) and Type 1 diabetes. On July 28, 2021, the Company as licensee and Melior Pharmaceuticals II, LLC (“Melior II”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic and is, to the best of our knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the Melior II Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5 On August 20, 2021, the Company as licensee, entered into an exclusive license agreement regarding the development and commercialization of Melior’s MLR-1023 (the “MLR-1023 Agreement”) with Melior Pharmaceuticals I, Inc. (“MP1”). The Company refers to MP2 and MP1 as “MP” or “Melior”. This second license is for the development and commercialization of MLR-1023, which is being developed as a novel therapeutic for Type 1 diabetes. Under the original terms of the MLR-1023 Agreement, if the Company failed to raise $4.0 million within 120 days of the effective date of the agreement, then the MLR-1023 Agreement would immediately terminate unless, by 120 days On October 20, 2021, the Company licensee expanded the exclusive licensing agreement with Melior I to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, if by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising. On February 16, 2022, an addendum to the MLR-1023 Agreement dated August 4, 2021 (the “First Addendum”), was executed by the Company and Melior, which extended the Raise Requirement to June 16, 2022. On July 18, 2022, the Company and Melior entered into the Second Addendum to the License Agreement (the “Second Addendum”). In accordance with the Second Addendum and subject to the terms and conditions therein, the Raise Requirement was extended to February 1, 2023, in exchange for a $ 136,921 500,000 As of February 1, 2023, the Company had not raised the additional $ 500,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) As of June 30, 2023, no performance milestones requiring cash consideration had been met under the MLR-1023 Agreement. To the extent that resources have been available, the Company has continued to work with its advisors in an effort to restructure our company and to identify potential strategic transactions to enhance the value of our company as such opportunities arise, including potential transactions and capital raising initiatives involving our current assets, as well as business combination transactions with operating companies. There can be no assurance that the Company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to us or at all. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the six months ended June 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2023, the Company had approximately $ 58,000 22.8 The Company has no revenues and has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss and net cash used in operating activities of approximately $ 615,000 626,000 22.8 56.4 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, the war in Ukraine, federal bank failures or other world-wide events, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Reverse Stock-split On September 30, 2022, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of 1-for-20. On October 5, 2022, the Company effected the 1-for-20 reverse stock split All disclosures of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of June 30, 2023, the Company had approximately $ 58,000 The Company deposits its cash with a major financial institution that may at times exceed the federally insured limit. As of June 30, 2023, the Company’s cash balance did not exceed the federal deposit insurance limit. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad levels. The following is a brief description of those six levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of June 30, 2023, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 4.3 4.13 5.55 263 408 0 1.10 Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at June 30, 2023 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 4,254 $ 4,254 Total $ - $ - $ 4,254 $ 4,254 A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Six Months Ended June 30, 2023 (In thousands) Warrants Notes Total Balance at December 31, 2022 $ 5,075 $ 1,311 $ 6,386 Initial valuation of derivative liabilities included in debt discount 407 - 407 Initial valuation of derivative liabilities included in derivative expense 565 - 565 Reclassification of derivative liabilities to gain on debt extinguishment - (80 ) (80 ) Change in fair value included in derivative expense (income) (2,782 ) (242 ) (3,024 ) Balance at June 30, 2023 $ 3,265 $ 989 $ 4,254 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid-in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the warrant is treated as a derivative liability, the derivative liability is recorded at fair value and the difference between the derivative liability and debt discount is recorded as an initial derivative expense. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Recently Issued Accounting Pronouncements Recently Adopted In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company adopted ASU No. 2021-04 on January 1, 2022. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. Not Yet Adopted Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2023 2022 2023 2022 Three Months ended Six Months ended (in thousands except share and per share data) 2023 2022 2023 2022 Numerator Net income (loss) $ 271 $ 99 $ (615 ) $ 25 Dividends (26 ) (406 ) (53 ) (566 ) Net Loss allocable to common stockholders $ 245 $ (307 ) $ (668 ) $ (541 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic 3,462,539 1,140,083 3,260,540 2,003,921 Net loss per share of common stock, basic Net loss per share $ 0.07 $ (0.27 ) $ (0.20 ) $ (0.27 ) Income loss per share - diluted Numerator Net Loss allocable to common stockholders - basic $ 245 $ (307 ) $ (668 ) $ (541 ) add back: Preferred stock dividends 26 Interest on convertible notes 59 Fair value adjustments on warrants and convertible notes (1,742 ) Net Loss allocable to common stockholders - diluted $ (1,412 ) $ (307 ) $ (668 ) $ (541 ) Denominator Weight Average common share - basic 3,462,539 1,140,083 3,260,540 2,003,921 add dilutive shares related to: Warrants 33,292,474 - - - Convertible notes 61,591,569 - - - Preferred stock 191,814 - - - Weighted average common shares outstanding used to compute net loss per share, diluted 98,538,396 1,140,083 3,260,540 2,003,921 Net loss per share of common stock, diluted Net loss per share $ (0.01 ) $ (0.27 ) $ (0.20 ) $ (0.27 ) The following number of shares for the three-month periods ended June 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 June 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 2,138,951 2,440,137 Warrants 32,252,367 5,132,784 Series C Preferred Stock - 3,334 Series D Preferred Stock - 2,500 Series E Preferred Stock 2,663 177,961 Total 34,393,981 7,775,716 The following number of shares for the six-month periods ended June 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: 2023 2022 June 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 63,730,520 2,440,137 Warrants 65,544,841 5,132,784 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 188,643 177,961 Total 129,469,838 7,775,716 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited)

Prepaid Expenses

Prepaid Expenses	6 Months Ended
	Jun. 30, 2023
Prepaid Expenses
Prepaid Expenses	Note 3 – Prepaid Expenses As of June 30, 2023, and December 31, 2022, prepaid expenses totaled approximately $ 24,000 47,000

Notes Payable and Convertible P

Notes Payable and Convertible Promissory Notes	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Notes Payable and Convertible Promissory Notes	Note 4 – Notes Payable and Convertible Promissory Notes The following table summarizes the Company’s outstanding term loans: Schedule of Outstanding Term Loans (in thousands) June 30, December 31, 2019 Term Loan $ 5,677 $ 5,677 2022 Term Loans 3,046 2,365 2023 Term Loans 1,332 - Notes payable 10,055 8,042 Unamortized discounts and fees (640 ) (709 ) Loans payable $ 9,415 $ 7,333 As of June 30, 2023, the 2019 Term Loan was in default. 2019 Term Loan During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes in the aggregate principal amount of approximately $ 5.7 707,000 The promissory notes accrued interest at a rate of 12 15 The unpaid principal balance of the notes, plus accrued and unpaid interest thereon, matured on June 28, 2020 On June 26, 2021, the holders of the 2019 Term Loans agreed to subordinate their lien and security interest in the assets of the Company and its subsidiaries as set forth in the Security Agreement dated June 28, 2019, to the holders of the June 2021 convertible notes. On April 19, 2022, a majority of the noteholders of the secured non-convertible promissory notes of the Company issued between June 18, 2019, and August 5, 2019, which matured on August 5, 2020, consented to forbear collection efforts until September 30, 2022. Accordingly, the collateral agent for the noteholders in consideration of the signed noteholder agreements agreed to forbear all notes outstanding. On November 16, 2022, holders of outstanding promissory notes representing a majority of the outstanding principal and accrued interest of the Notes, agreed to amend the Notes to make them automatically convertible into units consisting of a new series of convertible preferred stock and warrants upon an up listing financing transaction in which the Company’s common stock is listed on The Nasdaq Capital Market or the NYSE American, in exchange for the Holders agreeing to forbear repayment of their Notes and accrued interest until the Up listing Transaction has been completed. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The terms for the amendment of the Notes include no less than the following: ● The Notes will automatically convert upon the Uplisting Transaction into the Preferred Stock at 90 ● In addition, each Holder will receive 0.3 1.00 ● The shares of Preferred Stock will be subject to a six-month lock-up period from date of issuance; and ● The Company has agreed to register the Holders’ sale of the shares of common stock issuable upon conversion of the Preferred Stock and upon the exercise of the Warrants such that those shares will be freely tradeable following the up-list transaction and expiration of the lock-up period. The shares of the Preferred Stock will be entitled to vote on an as-converted-to-common basis together with the Company’s common stock. The shares of the Preferred Stock will automatically convert into shares of common stock upon expiration of the lock-up period at the conversion price of a percentage of a 30-day VWAP of common stock. The interest on the Notes, as accrued through the date of conversion, will convert into common stock at the offering price for the up-list transaction. The Company recognized approximately $ 212,300 422,300 As of June 30, 2023, the Company had approximately $ 3.3 5.7 3.3 2022 Term Loan – May On May 11, 2022, the Company entered into a Securities Purchase Agreement with investors whereby the Company issued the Purchasers Original Issue Discount Promissory Notes in the aggregate principal amount of $ 2,222,222 222,222 2,000,000 1,111,112 19,231 1,692,200 307,800 The Notes are due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. The Company recorded a total debt discount of $ 1,693,000 222,222 307,800 11,820 1,151,137 The Company’s obligations under the Notes are secured by a first priority lien on all of the assets of the Company and its wholly-owned subsidiaries pursuant to a Security Agreement, dated May 11, 2022 and among the Company, its wholly-owned subsidiaries, the Purchasers, and the lead investor as the collateral agent. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The Warrants were exercisable for a 66 November 11, 2027 0.80 On January 10, 2023, the conversion price of the warrants was adjusted to $ 0.56 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On May 11, 2023, the Company elected to extend the maturity date on the loan by six-months to November 11, 2023 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 During the three and six months ended June 30, 2023, the Company increased the outstanding principal amount of the notes by approximately $ 333,300 680,600 For the three and six months ended June 30, 2023, the Company recognized approximately $ 185,500 603,000 56,700 106,300 100,600 25,200 As of June 30, 2023, the Company has recorded approximately $ 2.9 222,400 2022 Term Loan – December On December 14, 2022, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which the Company issued and sold the investor a non-convertible Original Issue Discount Senior Secured Promissory Note in the principal amount of $ 142,857 158,537 100,000 82,400 17,600 42,857 The Notes are due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or December 14, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The unpaid principal amount of this Note, together with any interest accrued but unpaid thereon, may, at the sole discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company on the closing date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”). The Company recorded a total debt discount of $ 111,523 42,857 17,600 51,066 The Company’s obligations under the Notes are secured by a first priority lien on all of the assets of the Company and its wholly-owned subsidiaries pursuant to a Security Agreement, dated May 11, 2022 and among the Company, its wholly-owned subsidiaries, the Purchasers, and the lead investor as the collateral agent. The Warrants were exercisable for a 66 June 15, 2028 0.82 On January 10, 2023, the conversion price of the warrants was adjusted to $ 0.56 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 For the three and six months ended June 30, 2023, the Company recognized approximately $ 27,800 55,300 2,800 5,700 No As of June 30, 2023, the Company has recorded $ 142,857 6,300 50,700 2023 Term Loans January 18, 2023 On January 18, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors pursuant to which the Company issued and sold the investors a non-convertible Original Issue 30 285,714 452,962 200,000 173,850 26,150 The Company also agreed to increase the principal amount of prior Original Issue Discount Promissory Notes issued to the investor in May 2022 by 25 277,777 277,777 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The Notes are due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or January 18, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. The unpaid principal amount of this Note, together with any interest accrued but unpaid thereon, may, at the sole discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company on the closing date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”). The Company recorded a total debt discount of $ 203,000 85,700 26,200 91,100 The Warrants were exercisable for a 66 July 18, 2028 0.82 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 During both the three and six months ended June 30, 2023, the Company increased the outstanding principal amount of the notes by approximately $ 64,300 For the three and six months ended June 30, 2023, the Company recognized approximately $ 50,600 91,200 6,800 11,400 No As of June 30, 2023, the Company has recorded $ 350,000 11,400 111,800 February 3, 2023 On February 3, 2023, the Company entered into a Securities Purchase Agreement with an affiliated accredited investor pursuant to which the Company issued and sold the investor a non-convertible Original Issue 30 267,857 424,652 150,000 133,900 16,100 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The Notes are due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or February 3, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. The unpaid principal amount of this Note, together with any interest accrued but unpaid thereon, may, at the sole discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company on the closing date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”) The Company recorded a total debt discount of approximately $ 224,000 64,300 53,600 16,100 90,000 The Warrants were exercisable for a 66 August 3, 2028 0.82 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 For the three six months ended June 30, 2023, the Company recognized approximately $ 55,800 90,800 5,500 8,900 No As of June 30, 2023, the Company has recorded $ 267,857 8,900 133,200 February 16, 2023 On February 16, 2023, the Company entered into a Securities Purchase Agreement with an affiliated accredited investor pursuant to which the Company issued and sold the investor a non-convertible Original Issue 30 214,286 339,722 150,000 133,850 16,150 The Company also agreed to increase the principal amount of prior Original Issue Discount Promissory Notes issued to the investor in May 2022 by 25 69,444 69,444 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The Notes are due on the earlier of (i) the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12 month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest The Notes may, at the discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company (the “Convertible Preferred Stock”) on the closing date of the Qualified Financing. In the event of the conversion, the holder will receive a number of shares of Convertible Preferred Stock equal to the quotient obtained by dividing (i) the unpaid principal amount of this Note (together with any interest accrued but unpaid thereon) by (ii) the closing price of the securities issued in the Qualified Financing on the closing date of the Qualified Financing. Upon issuance, the conversion price of the Convertible Preferred Stock will be equal to the closing price of the securities issued in the Qualified Financing, subject to adjustment. The Company recorded a total debt discount of $ 163,600 64,200 16,200 83,200 The Warrants were exercisable for a 66 August 16, 2028 0.82 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 During both the three and six months ended June 30, 2023, the Company increased the outstanding principal amount of the notes by approximately $ 64,300 For the three and six months ended June 30, 2023, the Company recognized approximately $ 40,800 60,500 5,300 7,400 No As of June 30, 2023, the Company has recorded $ 278,571 7,400 103,100 April 28, 2023 On April 28, 2023, the Company entered into a Securities Purchase Agreement with two affiliated accredited investors pursuant to which the Company issued and sold the investors a non-convertible Original Issue 30 285,714 452,964 200,000 200,000 The Company also agreed to increase the principal amount of prior Original Issue Discount Promissory Notes issued to the investor in May 2022 and January 2023 by 30 461,904 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The Notes are due on the earlier of (i) the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12 month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any) The Notes may, at the discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company (the “Convertible Preferred Stock”) on the closing date of the Qualified Financing. In the event of the conversion, the holder will receive a number of shares of Convertible Preferred Stock equal to the quotient obtained by dividing (i) the unpaid principal amount of this Note (together with any interest accrued but unpaid thereon) by (ii) the closing price of the securities issued in the Qualified Financing on the closing date of the Qualified Financing. Upon issuance, the conversion price of the Convertible Preferred Stock will be equal to the closing price of the securities issued in the Qualified Financing, subject to adjustment. The Company recorded a total debt discount of $ 166,400 85,700 80,700 The Warrants issued with promissory notes were exercisable for a 66 0.82 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 For both the three and six months ended June 30, 2023, the Company recognized approximately $ 29,200 5,800 No As of June 30, 2023, the Company has recorded $ 285,714 5,800 137,200 June 22, 2023 On June 22, 2023, the Company entered into a Securities Purchase Agreement with four accredited investors pursuant to which the Company issued and sold the investors a non-convertible Original Issue Discount Senior Secured Promissory Note in the principal amount of $ 150,000 3,000,000 105,000 The Notes are due on the earlier of (i) the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12 month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any). ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The Notes may, at the discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company (the “Convertible Preferred Stock”) on the closing date of the Qualified Financing. In the event of the conversion, the holder will receive a number of shares of Convertible Preferred Stock equal to the quotient obtained by dividing (i) the unpaid principal amount of this Note (together with any interest accrued but unpaid thereon) by (ii) the closing price of the securities issued in the Qualified Financing on the closing date of the Qualified Financing. Upon issuance, the conversion price of the Convertible Preferred Stock (the “Preferred Conversion Price”) will be equal to the closing price of the securities issued in the Qualified Financing, subject to adjustment. The Notes provide for certain customary events of default which include failure to maintain the required reserve of shares for the Warrants, a restatement of the financial statements of the Company resulting in a reduction to the stock price by an enumerated threshold, and certain other customary events of default, subject to certain exceptions and limitations. Upon an event of default, the Notes will become immediately due and payable at a 125 100 The Notes contain customary restrictive covenants which apply for as long as at least 75% of the Notes remain outstanding, including covenants against incurring new indebtedness or liens, repurchasing shares of common stock or common stock equivalents, paying dividends or distributions on equity securities, and transactions with affiliates, subject to certain exceptions and limitations. In addition, the SPA imposes certain additional negative covenants and obligations on the Company, including a prohibition on filing a registration statement (other than on Form S-8) unless at least 30% of the Notes have been repaid as of such filing, a prohibition on incurring new indebtedness at any time while any Notes are outstanding, and a 90-day restriction against issuing shares of common stock or common stock equivalents, subject to certain exceptions and limitations. The Company recorded a total debt discount of $ 106,800 45,000 61,800 The Warrants issued with promissory notes were exercisable for a 66 0.05 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 For both the three and six months ended June 30, 2023, the Company recognized approximately $ 2,600 3,100 No As of June 30, 2023, the Company has recorded $ 150,000 3,100 104,000 Convertible Promissory Notes The following table summarizes the Company’s outstanding convertible notes as of June 30, 2023, and December 31, 2022: Schedule of Convertible Promissory Notes (in thousands) June 30, 2023 December 31, 2022 Convertible Notes $ 1,176 $ 1,319 Unamortized discounts - (67 ) Convertible notes payable, net $ 1,176 $ 1,252 All convertible notes including accrued interest were in default as of the issuance date of this Report. As of June 30, 2023, accrued interest totaled approximately $ 532,900 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Secured Convertible Promissory Note – February 2020 On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes with a principal of $ 550,500 10 499,950 The Convertible Notes matured on August 5, 2020 10 18 Until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $ 10.00 70 60 1.00 The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the Warrants of approximately $ 322,000 30,000 53,000 21,000 38,000 381,000 On January 27, 2022, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.78 On January 10, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.56 On April 14, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.279 On April 28, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.18 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) On May 10, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.054 On June 23, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.036 The Company recognized $ 20,800 45,100 20,800 45,800 As of June 30, 2023, the Company remains in default on the repayment of $ 457,359 230,500 140 The 40% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10 58,055 52,500 5,555 December 26, 2020 10 14,000 18 The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.40 65 50,000 203,000 The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 On January 27, 2022, the conversion price of the note was adjusted to the lower of 65 0.78 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) On January 10, 2023, the conversion price of the note was adjusted to the lower of 65 0.56 On April 14, 2023, the conversion price of the note was adjusted to the lower of 65 0.279 On April 28, 2023, the conversion price of the note was adjusted to the lower of 65 0.18 On May 10, 2023, the conversion price of the note was adjusted to the lower of 65 0.054 On June 23, 2023, the conversion price of the note was adjusted to the lower of 65 0.036 For both the six months ended June 30, 2023, and June 30, 2022, the Company recognized approximately $ 2,600 5,300 As of June 30, 2023, the Company remains in default on the repayment of principal of $ 58,055 31,400 140 The 40% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10 111,111 100,000 1.40 70 1.00 The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. The Company recorded approximately $ 9,000 The interest rate on the note was 10 18 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Additionally, the Company issued the noteholder 79,366 1.60 1.00 47,619 57,000 0.16 262.27 0.92 The Company recorded a discount related to the warrants of approximately $ 66,000 6,000 5,000 45,000 69,000 5,000 4,000 On January 27, 2022, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.98 0.78 35,816 On January 10, 2023, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.78 0.56 64,001 On April 14, 2023, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.56 0.279 226,882 On April 28, 2023, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.279 0.18 251,794 On May 10, 2023, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.18 0.054 1,642,202 On June 23, 2023, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.054 0.036 1,170,913 As of June 30, 2023, 3,518,592 0.036 For both the six months ended June 30, 2023, and June 30, 2022, the Company recognized approximately $ 5,000 10,100 As of June 30, 2023, the Company has outstanding principal of $ 111,111 49,600 As of June 30, 2023, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Secured Convertible Promissory Note – January 2021 On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10 52,778 47,500 5,278 1.40 70 The obligations of the Com

Licensing Agreements

Licensing Agreements	6 Months Ended
	Jun. 30, 2023
Licensing Agreements
Licensing Agreements	Note 5 - Licensing Agreements Les Laboratories Servier As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions). On January 4, 2021, the licensor terminated the licensing agreement with the Company for the commercialization of Prestalia®. As of June 30, 2023 and December 31, 2022, the Company had $ 24,500 No ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 - Related Party Transactions Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. An unpaid balance for previous years services performed under the agreement of approximately $ 4,000 is included in due to related party in the accompanying consolidated balance sheets at June 30, 2023 and December 31, 2022. In addition, as of June 30, 2023 and December 31, 2022 the Company owed various officers and directors approximately $ 12,000 26,000

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 7 - Stockholders’ Equity Preferred Stock Adhera has authorized 100,000 1,000 90,000 1,200 220 3,500 2,200 6,000 Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 5,100 voting rights of 33.33 votes per 150.00 As of June 30, 2023, 100 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 300 voting rights of 62.5 votes per 80.00 5 As of June 30, 2023, 40 Series E Convertible Preferred Stock and Warrants The Series E Preferred Stock has a stated value of $ 5,000 8 10.00 February 10, 2020 On March 19, 2021, the exercise price of the Series E warrants was adjusted from $ 10.00 1.00 25,900 25,900 On January 27, 2022, the exercise price of the Series E warrants was adjusted to $ 0.78 0.78 On May 17, 2022, the Company effected the conversion of 3,059 5.1 2,035,306 10.00 On January 10, 2023, the exercise price of the Series E warrants was adjusted to $ 0.56 0.56 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On May 17, 2023, a total of 1,453,028 The Company had accrued dividends on the Series E Preferred stock of approximately $ 525,000 At June 30, 2023, there were 267 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Series F Convertible Preferred Shares and Warrants The Series F Preferred Stock has a stated value of $ 5,000 8 10.00 February 10, 2020 On March 19, 2021, the exercise price of the Series F warrants was adjusted from $ 10.00 1.00 25,900 25,900 31,000 0.16 262.27 .46 .53 On January 27, 2022, the exercise price of the Series F warrants was adjusted to $ 0.78 0.78 On May 17, 2022, the Company effected the conversion of 358 543,000 233,127 10.00 On January 10, 2023, the exercise price of the Series F warrants was adjusted to $ 0.56 0.56 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 As of June 30, 2023, the Company had a total of 154,425 At June 30, 2023, and December 31, 2022, there were no Series F Preferred shares outstanding. Series G Convertible Preferred Shares The Series G Preferred Stock has a stated value of $ 5,000 8 10.00 As of June 30, 2023, and December 31, 2022, no ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Common Stock On January 27, 2022, the Company issued 12,721 9,500 422 28,000 18,000 23,000 23,000 5,000 On March 15, 2022, the Company issued 2,500 3,596 On March 15, 2022, the Company issued 10,000 14,384 On May 11, 2022, the Company issued 19,231 11,820 On May 17, 2022, the Company effected the conversion of 3,059 5.1 2,035,306 10.00 On May 17, 2022, the Company effected the conversion of 358 541,000 233,127 10.00 On January 10, 2023, the Company issued 17,861 3,839 6,161 0.56 5,500 On April 14, 2023, the holder of the March 15, 2022, convertible note converted $ 10,000 0.28 35,716 On April 28, 2023, the holder of the March 15, 2022, convertible note converted $ 21,314 6,586 0.18 155,000 On May 10, 2023, the holder of the March 15, 2022, convertible note converted $ 6,001 489 0.054 120,000 On May 30, 2023, the holder of the March 15, 2022, convertible note converted $ 9,203 756 0.059 170,000 On June 23, 2023, the holder of the March 15, 2022, convertible note converted $ 5,697 799 0.039 180,000 Treasury Stock On May 12, 2022, the Company repurchased 5,954 2,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) Warrants As of June 30, 2023, there were 65,544,841 0.04 Schedule of Stockholder’ Equity Note, Warrants or Rights Warrants issued with: Shares 2023 2024 2025 2026 2027 and Series F Preferred Stock 154,425 154,425 - - - - Bridge Loans 5,939,950 - - - - 5,939,950 Convertible Notes (CVN) 59,433,025 - 2,153,466 49,810,259 7,469,299 - Other 17,441 504 16,775 162 - - Total Warrants 65,544,841 1,54,929 2,170,241 49,810,421 7,469,299 5,939,950 The above table includes 65,479,780 Schedule of Warrants Shares Warrants as of December 31, 2022 6,785,914 Issued as a result of price adjustments on convertible notes 12,487,902 Variable quantity of warrants related to the February 2020 note 43,121,004 Warrants issued with 2023 Bridge Notes 4,670,301 Expirations (1,520,280 ) Warrants as of June 30, 2023 65,544,841 The intrinsic value of outstanding warrants as of June 30, 2023, was approximately $ 1.6 As discussed in Note 2 above, the Company has issued convertible notes and warrants with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock and various default provisions related to the payment of the notes in Company stock. The number of shares of common stock to be issued under the convertible notes and warrants is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the convertible notes is therefore, indeterminate. Due to the fact that the number of shares of common stock are indeterminable, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative as of that date. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the warrants were recorded as derivative liabilities. On June 30, 2023, the Company evaluated all outstanding warrants to determine whether these instruments are tainted and, due to reasons discussed above, all warrants outstanding were considered tainted and were therefore, accounted for as derivative liabilities. Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain warrants to reduce certain conversion prices during the six-month period to $ 0.036 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited)

Stock Incentive Plans

Stock Incentive Plans	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock Incentive Plans	Note 8 - Stock Incentive Plans Stock Options The following table summarizes stock option activity for the six months ended June 30, 2023: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2022 19,000 $ 19.60 Options expired / forfeited (19,000 ) $ 19.60 Outstanding, June 30, 2023 - $ - Exercisable, June 30, 2023 - $ - No

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 - Commitments and Contingencies Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs. Licensing Agreement – MLR 1019 On July 28, 2021, the Company and Melior II entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use Melior II’s Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 5 The license agreement terminates upon the last expiration of the patents licensed by the Company, which is presently 2038 subject to any potential extensions and renewals of any of such patents. If the Company fails to have its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using Melior II’s data shall terminate. Additionally, if the Company has completed the necessary steps to effect an Uplisting Event, the Company will have the option to purchase all rights held by Melior II on the MLR-1019 licensed products in consideration for 10 2.5 As of June 30, 2023, no performance milestones requiring cash consideration had been met under the agreement. Licensing Agreement – MLR 1023 On August 20, 2021, we as licensee entered into the exclusive license agreement regarding the development and commercialization of Melior’s MLR-1023 (the “MLR-1023 Agreement”) with Melior Pharmaceuticals I, Inc. (“MP1”). We refer to MP2 and MP1 as “MP” or “Melior”. This second license is for the development and commercialization of MLR-1023, which is being developed as a novel therapeutic for Type 1 diabetes. Under the original terms of the MLR-1023 Agreement, if the Company failed to raise $4.0 million within 120 days of the effective date of the agreement then the MLR-1023 Agreement would immediately terminate unless, by 120 days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 days would be provided to allow for the completion of the raise (the “Raise Requirement”). ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) On October 20, 2021, we as licensee expanded the exclusive licensing agreement with Melior I to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising On February 16, 2022, an addendum to the MLR-1023 Agreement dated August 4, 2021 (the “First Addendum”), was executed by the Company and Melior, which extended the Raise Requirement to June 16, 2022. On July 20, 2022, the Company and Melior entered into the Second Addendum to the License Agreement (the “Second Addendum”). In accordance with the Second Addendum and subject to the terms and conditions therein, the Raise Requirement was extended to February 1, 2023, in exchange for a $ 136,921 500,000 As of February 1, 2023, the Company had not raised the additional $ 500,000 On February 16, 2022, an addendum to the MLR-1023 Agreement dated August 4, 2021 (the “First Addendum”), was executed by the Company and Melior, which extended the requirement by t he Company to raise $4 million (the “Raise Requirement”) to June 16, 2022. On July 18, 2022, the Company and Melior entered into the Second Addendum to the License Agreement (the “Second Addendum”). In accordance with the Second Addendum and subject to the terms and conditions therein, the Raise Requirement was extended to February 1, 2023, in exchange for a $ 136,921 500,000 As of February 1, 2023, the Company had not raised the additional $ 500,000 As of June 30, 2023, no performance milestones requiring cash consideration had been met under the agreement.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 10 - Subsequent Events Conversion of Principal on Convertible Note On July 27, 2023, the holder of the June 25, 2021, convertible note converted $ 2,250 805 0.016 187,966 On August 10, 2023, the holder of the June 25, 2021, convertible note converted $ 2,000 734 0.013 196,085

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the six months ended June 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive.
Going Concern and Management’s Liquidity Plans	Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2023, the Company had approximately $ 58,000 22.8 The Company has no revenues and has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss and net cash used in operating activities of approximately $ 615,000 626,000 22.8 56.4 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, the war in Ukraine, federal bank failures or other world-wide events, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.
Reverse Stock-split	Reverse Stock-split On September 30, 2022, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of 1-for-20. On October 5, 2022, the Company effected the 1-for-20 reverse stock split All disclosures of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of June 30, 2023, the Company had approximately $ 58,000 The Company deposits its cash with a major financial institution that may at times exceed the federally insured limit. As of June 30, 2023, the Company’s cash balance did not exceed the federal deposit insurance limit.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited)
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad levels. The following is a brief description of those six levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of June 30, 2023, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 4.3 4.13 5.55 263 408 0 1.10 Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at June 30, 2023 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 4,254 $ 4,254 Total $ - $ - $ 4,254 $ 4,254 A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Six Months Ended June 30, 2023 (In thousands) Warrants Notes Total Balance at December 31, 2022 $ 5,075 $ 1,311 $ 6,386 Initial valuation of derivative liabilities included in debt discount 407 - 407 Initial valuation of derivative liabilities included in derivative expense 565 - 565 Reclassification of derivative liabilities to gain on debt extinguishment - (80 ) (80 ) Change in fair value included in derivative expense (income) (2,782 ) (242 ) (3,024 ) Balance at June 30, 2023 $ 3,265 $ 989 $ 4,254 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited)
Convertible Debt and Warrant Accounting	Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid-in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the warrant is treated as a derivative liability, the derivative liability is recorded at fair value and the difference between the derivative liability and debt discount is recorded as an initial derivative expense. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Recently Adopted In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company adopted ASU No. 2021-04 on January 1, 2022. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. Not Yet Adopted Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022 (unaudited) The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2023 2022 2023 2022 Three Months ended Six Months ended (in thousands except share and per share data) 2023 2022 2023 2022 Numerator Net income (loss) $ 271 $ 99 $ (615 ) $ 25 Dividends (26 ) (406 ) (53 ) (566 ) Net Loss allocable to common stockholders $ 245 $ (307 ) $ (668 ) $ (541 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic 3,462,539 1,140,083 3,260,540 2,003,921 Net loss per share of common stock, basic Net loss per share $ 0.07 $ (0.27 ) $ (0.20 ) $ (0.27 ) Income loss per share - diluted Numerator Net Loss allocable to common stockholders - basic $ 245 $ (307 ) $ (668 ) $ (541 ) add back: Preferred stock dividends 26 Interest on convertible notes 59 Fair value adjustments on warrants and convertible notes (1,742 ) Net Loss allocable to common stockholders - diluted $ (1,412 ) $ (307 ) $ (668 ) $ (541 ) Denominator Weight Average common share - basic 3,462,539 1,140,083 3,260,540 2,003,921 add dilutive shares related to: Warrants 33,292,474 - - - Convertible notes 61,591,569 - - - Preferred stock 191,814 - - - Weighted average common shares outstanding used to compute net loss per share, diluted 98,538,396 1,140,083 3,260,540 2,003,921 Net loss per share of common stock, diluted Net loss per share $ (0.01 ) $ (0.27 ) $ (0.20 ) $ (0.27 ) The following number of shares for the three-month periods ended June 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 June 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 2,138,951 2,440,137 Warrants 32,252,367 5,132,784 Series C Preferred Stock - 3,334 Series D Preferred Stock - 2,500 Series E Preferred Stock 2,663 177,961 Total 34,393,981 7,775,716 The following number of shares for the six-month periods ended June 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: 2023 2022 June 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 63,730,520 2,440,137 Warrants 65,544,841 5,132,784 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 188,643 177,961 Total 129,469,838 7,775,716
Stock-Based Compensation	Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Fair Value Measurements	Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at June 30, 2023 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 4,254 $ 4,254 Total $ - $ - $ 4,254 $ 4,254
Schedule of Roll Forward of Level 3 Financial Instruments	A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Six Months Ended June 30, 2023 (In thousands) Warrants Notes Total Balance at December 31, 2022 $ 5,075 $ 1,311 $ 6,386 Initial valuation of derivative liabilities included in debt discount 407 - 407 Initial valuation of derivative liabilities included in derivative expense 565 - 565 Reclassification of derivative liabilities to gain on debt extinguishment - (80 ) (80 ) Change in fair value included in derivative expense (income) (2,782 ) (242 ) (3,024 ) Balance at June 30, 2023 $ 3,265 $ 989 $ 4,254
Schedule of Earnings Per Share, Basic and Diluted	The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2023 2022 2023 2022 Three Months ended Six Months ended (in thousands except share and per share data) 2023 2022 2023 2022 Numerator Net income (loss) $ 271 $ 99 $ (615 ) $ 25 Dividends (26 ) (406 ) (53 ) (566 ) Net Loss allocable to common stockholders $ 245 $ (307 ) $ (668 ) $ (541 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic 3,462,539 1,140,083 3,260,540 2,003,921 Net loss per share of common stock, basic Net loss per share $ 0.07 $ (0.27 ) $ (0.20 ) $ (0.27 ) Income loss per share - diluted Numerator Net Loss allocable to common stockholders - basic $ 245 $ (307 ) $ (668 ) $ (541 ) add back: Preferred stock dividends 26 Interest on convertible notes 59 Fair value adjustments on warrants and convertible notes (1,742 ) Net Loss allocable to common stockholders - diluted $ (1,412 ) $ (307 ) $ (668 ) $ (541 ) Denominator Weight Average common share - basic 3,462,539 1,140,083 3,260,540 2,003,921 add dilutive shares related to: Warrants 33,292,474 - - - Convertible notes 61,591,569 - - - Preferred stock 191,814 - - - Weighted average common shares outstanding used to compute net loss per share, diluted 98,538,396 1,140,083 3,260,540 2,003,921 Net loss per share of common stock, diluted Net loss per share $ (0.01 ) $ (0.27 ) $ (0.20 ) $ (0.27 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following number of shares for the three-month periods ended June 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 June 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 2,138,951 2,440,137 Warrants 32,252,367 5,132,784 Series C Preferred Stock - 3,334 Series D Preferred Stock - 2,500 Series E Preferred Stock 2,663 177,961 Total 34,393,981 7,775,716 The following number of shares for the six-month periods ended June 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: 2023 2022 June 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 63,730,520 2,440,137 Warrants 65,544,841 5,132,784 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 188,643 177,961 Total 129,469,838 7,775,716

Notes Payable and Convertible_2

Notes Payable and Convertible Promissory Notes (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Outstanding Term Loans	The following table summarizes the Company’s outstanding term loans: Schedule of Outstanding Term Loans (in thousands) June 30, December 31, 2019 Term Loan $ 5,677 $ 5,677 2022 Term Loans 3,046 2,365 2023 Term Loans 1,332 - Notes payable 10,055 8,042 Unamortized discounts and fees (640 ) (709 ) Loans payable $ 9,415 $ 7,333
Schedule of Convertible Promissory Notes	The following table summarizes the Company’s outstanding convertible notes as of June 30, 2023, and December 31, 2022: Schedule of Convertible Promissory Notes (in thousands) June 30, 2023 December 31, 2022 Convertible Notes $ 1,176 $ 1,319 Unamortized discounts - (67 ) Convertible notes payable, net $ 1,176 $ 1,252
Schedule of Fair Value of Derivative liabilities Estimated Issuance and Valuation Mode	During the six months ended June 30, 2023, the fair value of the derivative liabilities was estimated at issuance and at the June 30, 2023, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.00 1.10 Volatility 178.2 409 % Risk-free interest rate 3.36 5.55 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of Stockholder’ Equity Note, Warrants or Rights	Schedule of Stockholder’ Equity Note, Warrants or Rights Warrants issued with: Shares 2023 2024 2025 2026 2027 and Series F Preferred Stock 154,425 154,425 - - - - Bridge Loans 5,939,950 - - - - 5,939,950 Convertible Notes (CVN) 59,433,025 - 2,153,466 49,810,259 7,469,299 - Other 17,441 504 16,775 162 - - Total Warrants 65,544,841 1,54,929 2,170,241 49,810,421 7,469,299 5,939,950
Schedule of Warrants	Schedule of Warrants Shares Warrants as of December 31, 2022 6,785,914 Issued as a result of price adjustments on convertible notes 12,487,902 Variable quantity of warrants related to the February 2020 note 43,121,004 Warrants issued with 2023 Bridge Notes 4,670,301 Expirations (1,520,280 ) Warrants as of June 30, 2023 65,544,841

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Share Based Payments Arrangement, Option Activity	The following table summarizes stock option activity for the six months ended June 30, 2023: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2022 19,000 $ 19.60 Options expired / forfeited (19,000 ) $ 19.60 Outstanding, June 30, 2023 - $ - Exercisable, June 30, 2023 - $ -

Organization and Business Ope_2

Organization and Business Operations (Details Narrative) - USD ($)							1 Months Ended
	Feb. 01, 2023	Jul. 20, 2022	Jul. 18, 2022	Nov. 17, 2021	Aug. 20, 2021	Aug. 20, 2021	Feb. 16, 2022	Jul. 28, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement commitments description				On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, if by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising.
Licensing Agreement MLR1019 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Gross sales percentage								5%
Licensing Agreement - MLR 1023 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement commitments description				On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising	On August 20, 2021, the Company as licensee, entered into an exclusive license agreement regarding the development and commercialization of Melior’s MLR-1023 (the “MLR-1023 Agreement”) with Melior Pharmaceuticals I, Inc. (“MP1”). The Company refers to MP2 and MP1 as “MP” or “Melior”. This second license is for the development and commercialization of MLR-1023, which is being developed as a novel therapeutic for Type 1 diabetes.	if the Company failed to raise $4.0 million within 120 days of the effective date of the agreement then the MLR-1023 Agreement would immediately terminate unless, by 120 days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 days would be provided to allow for the completion of the raise (the “Raise Requirement”).	he Company to raise $4 million (the “Raise Requirement”) to June 16, 2022.
Raise requirement description					the Company failed to raise $4.0 million within 120 days of the effective date of the agreement, then the MLR-1023 Agreement would immediately terminate unless, by 120 days
Licensing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for licensing agreement		$ 136,921	$ 136,921
Capital raise in additional	$ 500,000	$ 500,000	$ 500,000

Schedule of Fair Value Measurem

Schedule of Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Platform Operator, Crypto-Asset [Line Items]
Derivative liability	$ 4,254	$ 6,386
Total	4,254
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Derivative liability	4,254
Total	$ 4,254

Schedule of Roll Forward of Lev

Schedule of Roll Forward of Level 3 Financial Instruments (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Balance at December 31, 2022	$ 6,386
Initial valuation of derivative liabilities included in debt discount	407
Initial valuation of derivative liabilities included in derivative expense	565
Reclassification of derivative liabilities to gain on debt extinguishment	(80)
Change in fair value included in derivative expense (income)	(3,024)
Balance at June 30, 2023	4,254
Convertible Notes [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Balance at December 31, 2022	1,311
Initial valuation of derivative liabilities included in debt discount
Initial valuation of derivative liabilities included in derivative expense
Reclassification of derivative liabilities to gain on debt extinguishment	(80)
Change in fair value included in derivative expense (income)	(242)
Balance at June 30, 2023	989
Warrant [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Balance at December 31, 2022	5,075
Initial valuation of derivative liabilities included in debt discount	407
Initial valuation of derivative liabilities included in derivative expense	565
Reclassification of derivative liabilities to gain on debt extinguishment
Change in fair value included in derivative expense (income)	(2,782)
Balance at June 30, 2023	$ 3,265

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Accounting Policies [Abstract]
Net income (loss)	$ 271	$ (886)	$ 99	$ (74)	$ (615)	$ 25
Dividends	(26)		(406)		(53)	(566)
Net Loss allocable to common stockholders - basic	$ 245		$ (307)		$ (668)	$ (541)
Weight Average common share - basic	3,462,539		1,140,083		3,260,540	2,003,921
Net loss per share	$ 0.07		$ (0.27)		$ (0.20)	$ (0.27)
Preferred stock dividends	$ 26
Interest on convertible notes	59
Fair value adjustments on warrants and convertible notes	(1,742)
Net Loss allocable to common stockholders - diluted	(1,412)		$ (307)		$ (668)	$ (541)
Warrants	33,292,474
Convertible notes	61,591,569
Preferred stock	$ 191,814
Weighted average common shares outstanding used to compute net loss per share, diluted	98,538,396		1,140,083		3,260,540	2,003,921
Net loss per share	$ (0.01)		$ (0.27)		$ (0.20)	$ (0.27)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	34,393,981	7,775,716	129,469,838	7,775,716
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		19,000		19,000
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,138,951	2,440,137	63,730,520	2,440,137
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	32,252,367	5,132,784	65,544,841	5,132,784
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		3,334	3,334	3,334
Series D Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		2,500	2,500	2,500
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,663	177,961	188,643	177,961

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended				6 Months Ended
	Oct. 05, 2022	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cash		$ 58,000				$ 58,000		$ 32,000
Working capital		22,800,000				22,800,000
Net loss		(271,000)	$ 886,000	$ (99,000)	$ 74,000	615,000	$ (25,000)
Net cash used in operating activities						626,000	690,000
Stockholders deficit		22,787,000	$ 23,093,000	$ 19,995,000	$ 25,498,000	22,787,000	$ 19,995,000	22,186,000	$ 25,106,000
Accumulated deficit		56,418,000				$ 56,418,000		$ 55,751,000
Reverse stock split	1-for-20 reverse stock split
Minimum [Member]
Property, Plant and Equipment [Line Items]
Risk free interest rate						4.13%
Volatility rate						263%
Fair value assumptions, expected term						0 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Risk free interest rate						5.55%
Volatility rate						408%
Fair value assumptions, expected term						1 year 1 month 6 days
Fair Value, Inputs, Level 3 [Member]
Property, Plant and Equipment [Line Items]
Long term debt fair value		$ 4,300,000				$ 4,300,000

Prepaid Expenses (Details Narra

Prepaid Expenses (Details Narrative) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Prepaid Expenses
Prepaid expenses	$ 24,000	$ 47,000

Schedule of Outstanding Term Lo

Schedule of Outstanding Term Loans (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Notes payable	$ 10,055	$ 8,042
Unamortized discounts and fees	(640)	(709)
Loans payable	9,415	7,333
2019 Term Loan [Member]
Short-Term Debt [Line Items]
Notes payable	5,677	5,677
2022 Term Loan [Member]
Short-Term Debt [Line Items]
Notes payable	3,046	2,365
2023 Term Loan [Member]
Short-Term Debt [Line Items]
Notes payable	$ 1,332

Schedule of Convertible Promiss

Schedule of Convertible Promissory Notes (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes	$ 1,176	$ 1,319
Unamortized discounts		(67)
Convertible notes payable, net	$ 1,176	$ 1,252

Schedule of Fair Value of Deriv

Schedule of Fair Value of Derivative liabilities Estimated Issuance and Valuation Mode (Details)	Jun. 30, 2023
Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability rate	0
Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Term (in years)	0 years
Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Term (in years)	1 year 1 month 6 days
Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability rate	178.2
Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability rate	409
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability rate	3.36
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability rate	5.55

Notes Payable and Convertible_3

Notes Payable and Convertible Promissory Notes (Details Narrative)																																									3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 23, 2023 USD ($) $ / shares shares	Jun. 22, 2023 USD ($) $ / shares shares	May 30, 2023 USD ($) $ / shares shares	May 10, 2023 USD ($) $ / shares shares	May 10, 2023 USD ($) $ / shares shares	Apr. 28, 2023 USD ($) $ / shares shares	Apr. 14, 2023 USD ($) $ / shares shares	Mar. 13, 2023 USD ($)	Mar. 09, 2023 USD ($)	Feb. 17, 2023 USD ($)	Feb. 16, 2023 USD ($) $ / shares shares	Feb. 03, 2023 USD ($) $ / shares shares	Feb. 01, 2023 USD ($)	Jan. 23, 2023 USD ($)	Jan. 18, 2023 USD ($) $ / shares shares	Jan. 10, 2023 USD ($) $ / shares shares	Dec. 14, 2022 USD ($) $ / shares shares	Nov. 16, 2022 $ / shares	Sep. 16, 2022 USD ($)	Jun. 27, 2022 USD ($)	May 12, 2022 USD ($) shares	May 11, 2022 USD ($) $ / shares shares	Mar. 15, 2022 USD ($) shares	Jan. 27, 2022 USD ($) $ / shares shares	Jan. 05, 2022	Nov. 15, 2021	Nov. 09, 2021	Nov. 04, 2021 shares	Oct. 07, 2021 USD ($) $ / shares shares	Oct. 04, 2021 USD ($) $ / shares shares	Aug. 17, 2021 USD ($) $ / shares shares	Aug. 11, 2021 USD ($) $ / shares shares	Jun. 25, 2021 USD ($) $ / shares shares	Apr. 12, 2021 USD ($) $ / shares shares	Jan. 31, 2021 USD ($) $ / shares shares	Oct. 30, 2020 USD ($) $ / shares shares	Jun. 26, 2020 USD ($) $ / shares	May 05, 2020 $ / shares	Feb. 05, 2020 USD ($)	Dec. 28, 2019	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2019 USD ($)	May 11, 2023	Jan. 02, 2022	Nov. 30, 2021 $ / shares shares	Oct. 12, 2021	Jul. 31, 2021	Apr. 30, 2021	Mar. 19, 2021 USD ($) $ / shares shares	Jan. 25, 2021	Aug. 05, 2020	Jun. 15, 2020	Aug. 05, 2019 USD ($)
Short-Term Debt [Line Items]
Repayments of debt																																											$ 95,000	$ 407,000
Class of warrants | shares																																									65,544,841		65,544,841		6,785,914
Payments of Debt Issuance Costs																																											$ 58,000	328,000
Debt description															the 12-month anniversary of the original issuance date of the Notes, or January 18, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.		(i) the 12-month anniversary of the original issuance date of the Notes, or December 14, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.
Debt discount																																											1,000,000	488,000
Debt discount to be amortized																																									$ 640,000		640,000		$ 709,000
Loan inducement fee																																									462,000		809,000
Convertible notes payable current																																									1,176,000		1,176,000		1,252,000
Warrants and rights outstanding																																									1,671,294		1,671,294
Notes payable																																									10,055,000		10,055,000		8,042,000
Interest expense debt																																									36,000	210,000	75,000	215,000
Interest rate																			18%						16%
Reclassification of additional paid in capital to derivative liability																																														$ 3,462,000
Loss on fair value of derivative liabilities																																											2,459,000	1,679,000
Change in the fair value of derivative liabilities																																									(1,742,000)
Related Party [Member]
Short-Term Debt [Line Items]
Interest expense related party																			$ 32,000
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Interest payable																																									$ 532,900		532,900
Convertible Debt [Member]
Short-Term Debt [Line Items]
Principal amount	$ 799		$ 756	$ 489	$ 489	$ 6,586										$ 1,661
Debt instrument, convertible, conversion price | $ / shares	$ 0.036		$ 0.059	$ 0.054	$ 0.054	$ 0.18	$ 0.28									$ 0.56
Debt conversion, converted instrument, amount	$ 5,697		$ 9,203	$ 6,001		$ 21,314	$ 10,000									$ 3,839
February 16 Term Loan [Member]
Short-Term Debt [Line Items]
Loan inducement fee											$ 69,444
February 2020 Convertible Note [Member]
Short-Term Debt [Line Items]
Interest expense																$ 6,161
Debt interest amount, conversion of common stock, shares | shares																17,861
Interest expense debt																$ 5,500
Senior Secured Convertible Promissory Note [Member] | Convertible Note [Member]
Short-Term Debt [Line Items]
Principal amount																																					$ 58,055																					$ 5,700,000
Debt issuance costs																																					$ 14,000
Interest rate, percentage																																					10%
Maturity date																																					Dec. 26, 2020
Interest expense																																											$ 2,600	5,300
Proceeds from issuance of secured debt																																					$ 52,500
Debt discount to be amortized																																					$ 5,555
Debt instrument, convertible, conversion price | $ / shares	$ 0.036			$ 0.054	$ 0.054	$ 0.18	$ 0.279									$ 0.56								$ 0.78													$ 0.40
Debt instrument interest rate, effective percentage																																					10%																			18%
Debt conversion converted instrument rate	65%			65%		65%	65%									65%								65%													65%
Convertible, beneficial conversion feature																																					$ 50,000
Beneficial conversion feature																																					$ 203,000
Senior Secured Convertible Promissory Note [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares																																									$ 0.036		$ 0.036
Secured Convertible Promissory Note [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Principal amount																																									$ 58,055		$ 58,055
Interest rate, percentage																																									140%		140%
Convertible note premium description																																											The 40% premium will be recorded once a demand occurs.
Accrued interest																																									$ 31,400		$ 31,400
Senior Secured Convertible Promissory Note One [Member]
Short-Term Debt [Line Items]
Principal amount																																				$ 111,111					$ 111,111		$ 111,111
Debt issuance costs																																				$ 9,000
Interest rate, percentage																																				10%					125%		125%
Warrants exercise price per share | $ / shares																																									$ 0.036		$ 0.036											$ 1
Interest expense																																											$ 5,000	10,100
Accured interest																																									$ 49,600		$ 49,600
Proceeds from issuance of secured debt																																				$ 100,000
Class of warrants | shares																38,303																				79,366																		47,619
Debt discount to be amortized																																				$ 6,000
Warrant term																																																						11 months 1 day
Debt instrument, convertible, conversion price | $ / shares																																				$ 1.40																		$ 1
Debt instrument interest rate, effective percentage																																																					18%
Shares issued, price per share | $ / shares																																				$ 1.60
Convertible note premium description																																											The 25% premium will be recorded once a demand occurs.
Convertible, beneficial conversion feature																																				$ 45,000
Beneficial conversion feature																																				$ 69,000
Threshold percentage																																				70%
Deemed dividend																																																						$ 57,000
Number of warrants or rights outstanding | shares																																									3,518,592		3,518,592
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																																						0.16
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																																						262.27
Senior Secured Convertible Promissory Note One [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt issuance costs																																				$ 4,000
Debt discount																																				5,000
Senior Secured Convertible Promissory Note One [Member] | October 2020 [Member]
Short-Term Debt [Line Items]
Class of warrants | shares	1,170,913			1,642,202	1,642,202	251,794	226,882									64,001								35,816
Senior Secured Convertible Promissory Note One [Member] | October 2020 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt and warrant exercise price per share | $ / shares	$ 0.054			$ 0.18	$ 0.18	$ 0.279	$ 0.56									$ 0.78								$ 0.98
Senior Secured Convertible Promissory Note One [Member] | October 2020 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt and warrant exercise price per share | $ / shares	$ 0.036			$ 0.054	$ 0.054	$ 0.18	$ 0.279									$ 0.56								$ 0.78
Senior Secured Convertible Promissory Note - January 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																																			$ 52,778
Debt issuance costs																																			$ 2,000
Interest rate, percentage																																			10%
Warrants exercise price per share | $ / shares																																			$ 1.60
Interest expense																																											$ 2,400	4,800
Accured interest																																									$ 21,100		$ 21,100
Original issue discount																																			$ 35,000
Class of warrants | shares																																			37,699																			22,619
Debt discount to be amortized																																			$ 2,000
Warrant term																																																						11 months 19 days
Debt instrument, convertible, conversion price | $ / shares																																			$ 1.40																			$ 1
Debt instrument interest rate, effective percentage																																			10%						125%		125%									18%
Convertible notes payable current																																			$ 47,500
Convertible note premium description																																											The 25% premium will be recorded once a demand occurs.
Deemed dividend																																																						$ 27,000
Conversion ratio																																			70
Fair value method																																			$ 1,000
Notes payable																																									$ 52,778		$ 52,778
Senior Secured Convertible Promissory Note - January 2021 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Class of warrants | shares	556,171			780,028	780,028	119,600	107,767									30,398								17,012
Debt and warrant exercise price per share | $ / shares	$ 0.054			$ 0.18	$ 0.18	$ 0.279	$ 0.56									$ 0.78								$ 0.98																	$ 0.036		$ 0.036
Senior Secured Convertible Promissory Note - January 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt and warrant exercise price per share | $ / shares	$ 0.036			$ 0.054	$ 0.054	$ 0.18	$ 0.279									0.56								$ 0.78
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																																						0.16
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																																						262.27
Senior Secured Convertible Promissory Note - January 2021 [Member] | Investor and Lender [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized																																			5,278
Senior Secured Convertible Promissory Note Three [Member]
Short-Term Debt [Line Items]
Principal amount																																		$ 66,667							$ 41,667		$ 41,667
Interest rate, percentage																																		10%							125%		125%
Warrants exercise price per share | $ / shares																																	$ 1.50								$ 0.036		$ 0.036							$ 1
Interest expense																																									$ 3,400		$ 6,800
Accured interest																																									$ 20,200		$ 20,200
Original issue discount																																		$ 6,667
Class of warrants | shares	700,781			982,843	982,843	150,697	135,787																	16,147									10,667																	19,084
Debt discount																																		3,000
Debt discount to be amortized																																		$ 34,000
Debt instrument, convertible, conversion price | $ / shares																								$ 0.78										$ 1.50																$ 1
Debt instrument interest rate, effective percentage																																		10%																	18%
Convertible notes payable current																																		$ 60,000
Debt conversion converted instrument rate																																		70%
Convertible note premium description																																											The 25% premium will be recorded once a demand occurs.
Number of warrants or rights outstanding | shares																																									2,105,846		2,105,846
Senior Secured Convertible Promissory Note Three [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares																								1.05
Debt and warrant exercise price per share | $ / shares	$ 0.054			$ 0.054	$ 0.054	$ 0.279	$ 0.279									0.56
Senior Secured Convertible Promissory Note Three [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares																								$ 0.78
Debt and warrant exercise price per share | $ / shares	$ 0.036			$ 0.18	$ 0.18	$ 0.18	$ 0.56									$ 0.78
Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																		0.89
Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																		240.64
Senior Secured Convertible Promissory Note Three [Member] | Investor [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																																		$ 1.90
Class of warrants | shares																																		40,000
Warrant term																																		5 years
Senior Secured Convertible Promissory Note Three [Member] | April 2021 [Member]
Short-Term Debt [Line Items]
Class of warrants | shares	527,891			740,366	740,366	113,518	102,305									28,834
Debt instrument, convertible, conversion price | $ / shares																$ 0.56
Senior Secured Convertible Promissory Note Three [Member] | April 2021 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	$ 0.054			$ 0.18	$ 0.18	$ 0.279	$ 0.56									0.78
Senior Secured Convertible Promissory Note Three [Member] | April 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	0.036			0.054	0.054	0.18	0.279									0.56
Senior Secured Convertible Promissory Note Three [Member] | April 2021 Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Interest expense																																									$ 1,900	3,000	$ 3,800	6,000
Warrant exercise price increase decrease | $ / shares																																											$ 0.036
Number of warrants or rights outstanding | shares																																									1,586,311		1,586,311
Senior Secured Convertible Promissory Note Three [Member] | June 2021 Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Interest expense																																										3,400		7,000
Debt discount																																										9,900		19,600
Senior Secured Convertible Promissory Note Three [Member] | June 2021 Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount																																									$ 57,000		$ 57,000
Accured interest																																									25,900		25,900
April 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Shares issued for warrants exercise | shares																												7,662
Cashless exercise of warrants | shares																												12,500
Senior Secured Convertible Promissory Note - June 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																																	$ 66,500
Interest rate, percentage																																	10%
Warrants exercise price per share | $ / shares																																	$ 1.90
Interest expense																								$ 421
Original issue discount																																	$ 3,500
Class of warrants | shares																								21,436									40,000
Number of shares issued | shares																																	2,377
Debt discount																																	$ 15,784
Debt discount to be amortized																																	5,040
Debt issuance costs																																	$ 9,300
Warrant term																																	6 years
Debt instrument, convertible, conversion price | $ / shares																								$ 0.78									$ 1.50
Debt instrument interest rate, effective percentage																																	5%
Debt interest amount, conversion of common stock, shares | shares																								12,721
Convertible notes payable current																																	$ 63,000
Debt conversion converted instrument rate																																	65%
Warrants and rights outstanding																																	$ 76,000
Derivative liabilities																																	102,823
Derivative expense																																	87,039
Debt discount																																	66,500
Unamortized debt issuance expense																																	$ 9,300
Debt conversion, converted instrument, amount																								$ 9,500
Trading securities debt																								28,000
Loss on extinguishment of debt																								18,000
Derivative fair value of derivative net																								23,000
Gain on extinguishment of debt																				$ 23,000
Extinguishment of debt gain loss net of tax																								$ 5,000
Senior Secured Convertible Promissory Note - June 2021 [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares																								$ 0.78
Senior Secured Convertible Promissory Note - June 2021 [Member] | October 4 2021 Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount																																									14,200		14,200
Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																																$ 220,500									84,800		84,800
Debt issuance costs																																$ 30,000
Interest rate, percentage																																10%
Maturity date																					Sep. 30, 2022
Warrants exercise price per share | $ / shares	1.60			1.60	1.60	1.60	1.60									1.60								1.60																										$ 1
Accured interest																																									$ 58,900		$ 58,900
Debt payment Interest																					$ 64,305
Original issue discount																																$ 10,500
Class of warrants | shares																																40,000																		36,000
Debt discount																																$ 106,505
Debt discount to be amortized																																$ 30,000
Debt instrument, convertible, conversion price | $ / shares	$ 0.036			$ 0.054	0.054	$ 0.18	$ 0.279									$ 0.56								$ 0.78								$ 1.50																		$ 1
Interest payable																					54,278
Debt conversion converted instrument rate	65%			65%		65%	65%									65%								65%			24%					65%
Debt and warrant exercise price per share | $ / shares	$ 0.036			$ 0.054	0.054	$ 0.18	$ 0.279									$ 0.56
Warrants and rights outstanding																																$ 210,000
Debt instrument periodic payment principal																					128,502
Interest expense debt																					45,200
Derivative liabilities																																340,893
Derivative expense																																$ 234,388
Debt conversion shares issued or options issued | shares	700,781			982,843		150,697	135,787									38,303								21,436
Debt instrument periodic payment principal																					135,695
Convertible Promissory Note - August 11, 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares																																$ 1.60
Convertible Promissory Note - August 11, 2021 [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized																																$ 106,505
Convertible Promissory Note - August 11, 2021 [Member] | August 11,2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares	$ 0.036			$ 0.054	0.054	$ 0.18	$ 0.279									$ 0.56								$ 0.78																	$ 0.036		$ 0.036
Interest expense																																									$ 5,100	73,000	$ 10,100	85,400
Debt discount																																										40,000		94,000
Number of warrants or rights outstanding | shares																																									2,105,846		2,105,846
Additional interest accured																																										67,000
Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																															$ 220,500										$ 220,500		$ 220,500
Debt issuance costs																															$ 30,000
Interest rate, percentage																															10%
Warrants exercise price per share | $ / shares	1.60			1.60	1.60	1.60	1.60									1.60								1.60
Interest expense																																									12,600	244	25,000	5,200
Accured interest																																									$ 90,800		$ 90,800
Original issue discount																															$ 10,500
Class of warrants | shares																															40,000
Debt discount																															$ 100,571											32,700		65,000
Debt instrument, convertible, conversion price | $ / shares	$ 0.036			$ 0.054	0.054	$ 0.18	$ 0.279									$ 0.56								$ 0.78							$ 1.50
Debt conversion converted instrument rate	65%			65%		65%	65%									65%								65%							65%
Debt and warrant exercise price per share | $ / shares	$ 0.036			$ 0.054	0.054	$ 0.18	$ 0.279									$ 0.56								$ 0.78
Warrants and rights outstanding																															$ 210,000
Derivative liabilities																															398,404
Derivative expense																															$ 297,833
Debt conversion shares issued or options issued | shares	700,781			982,843		150,697	135,787									38,303								21,436
Convertible Promissory Note - August 17, 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares																															$ 1.60
Convertible Promissory Note - August 17, 2021 [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																																																		$ 1
Class of warrants | shares																																																		36,000
Debt discount to be amortized																															$ 100,571
Debt instrument, convertible, conversion price | $ / shares																																																		$ 1
Convertible Promissory Note - August 17, 2021 [Member] | August 11,2021 [Member]
Short-Term Debt [Line Items]
Number of warrants or rights outstanding | shares																																									2,105,846		2,105,846
Convertible Promissory Note - August 17, 2021 [Member] | August 17 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares	$ 0.036			$ 0.054	0.054	$ 0.18	$ 0.279									$ 0.56								$ 0.78																	$ 0.036		$ 0.036
Convertible Promissory Note - October 4, 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																														$ 131,250
Debt issuance costs																														$ 15,000
Interest rate, percentage																														10%																			16%
Interest expense																																									$ 600	244	$ 1,200	5,200
Original issue discount																														$ 6,250
Class of warrants | shares																														23,810
Debt discount																														$ 77,891												32,700		65,000
Debt discount to be amortized																														$ 131,250
Debt instrument, convertible, conversion price | $ / shares																0.56								0.78						$ 1.50
Debt interest amount, conversion of common stock, shares | shares																														2,173
Debt instrument periodic payment principal									$ 2,500												83,500
Derivative liabilities																														$ 564,943
Derivative expense																														487,052
Unamortized debt issuance expense																														32,109
Proceeds form warrants																														110,000
Agreegate exercise price amount																														45,238
Discount related issuance cost																														15,000
Commitment fee																					1,000
Convertible Promissory Note - October 4, 2021 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	0.054			0.054	0.054	0.279	0.279
Convertible Promissory Note - October 4, 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	0.036			0.18	0.18	0.18	0.56
Convertible Promissory Note - October 4, 2021 [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt payment Interest																					8,905
Debt instrument periodic payment principal																					31,042
Convertible Promissory Note - October 4, 2021 [Member] | October 4 2021 Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Accured interest																																									2,000		2,000
Interest expense debt																					96,000
Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																													$ 131,250												16,700		16,700
Debt issuance costs																													$ 15,000
Interest rate, percentage																													10%
Interest expense																																									700	295	1,300	5,300
Accured interest																																									2,100		2,100
Original issue discount																													$ 6,250
Class of warrants | shares																													23,810
Debt discount																													$ 76,517													32,700		65,100
Debt discount to be amortized																													$ 131,250
Debt instrument, convertible, conversion price | $ / shares																$ 0.56								$ 0.78					$ 1.50
Debt instrument periodic payment principal																					83,500
Interest expense debt																					98,000
Derivative liabilities																													$ 564,184
Derivative expense																													487,667
Proceeds form warrants																													110,000
Agreegate exercise price amount																													45,238
Discount related issuance cost																													15,000
Commitment fee																					$ 1,000
Convertible Promissory Note October 7, 2021 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	0.054			0.054	0.054	0.279	0.56
Convertible Promissory Note October 7, 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	0.036			0.18	0.18	0.18	0.279
Convertible Promissory Note October 7, 2021 [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt payment Interest																																													8,905
Debt discount to be amortized																													76,517
Debt instrument periodic payment principal																																													31,042
Convertible Promissory Note - March 15, 2022 [Member]
Short-Term Debt [Line Items]
Principal amount																							$ 250,000																		61,800		61,800
Interest rate, percentage																							10%
Interest expense																																									3,900	25,000	11,100	25,000
Accured interest																																									200		200
Debt payment Interest														$ 4,191																															31,400
Original issue discount																							$ 50,000
Proceeds from issuance of secured debt																							$ 200,000
Number of shares issued | shares																							10,000
Proceeds from Convertible Debt																							$ 180,000
Payments of Debt Issuance Costs																							20,000
Debt discount																							250,000																		0	62,300	50,000	74,000
Debt instrument periodic payment principal								$ 30,000		$ 32,500			$ 15,000	$ 10,819									39,285																						43,828
Interest expense debt																																									$ 36,400		$ 75,000		68,600
Discount related issuance cost																							34,384
Guaranteed Interest Contracts																							$ 25,000
Convertible Promissory Note - March 15, 2022 [Member] | Investor [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares																							2,500
Convertible Promissory Note - March 15, 2022 [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized																							$ 162,020
Common Stock [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	$ 0.036			$ 0.054	$ 0.054	$ 0.18	$ 0.279
Debt interest amount, conversion of common stock, shares | shares	120,000		170,000	120,000	120,000	155,000	35,716									17,861
Common Stock [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	$ 0.039
Debt interest amount, conversion of common stock, shares | shares	180,000
Common Stock [Member] | Senior Secured Convertible Promissory Note Three [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment principal																																													25,000
Interest expense debt																																													$ 19,500
Common Stock [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																																	$ 1.60
Common Stock [Member] | Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares																																7,000
Debt discount to be amortized																																$ 17,041
Common Stock [Member] | Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares																															5,631
Debt discount to be amortized																															$ 17,209
Common Stock [Member] | Convertible Promissory Note - October 4, 2021 [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares																					2,977
Debt discount to be amortized																														$ 77,891
Common Stock [Member] | Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares																					2,977
Debt discount to be amortized																													$ 33,483
Common Stock [Member] | Convertible Promissory Note - March 15, 2022 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized																							$ 3,596
Warrant [Member]
Short-Term Debt [Line Items]
Number of warrants or rights outstanding | shares																																									65,544,841		65,544,841
Warrant [Member] | Senior Secured Convertible Promissory Note One [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized																																				$ 66,000
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member]
Short-Term Debt [Line Items]
Debt issuance costs																																			1,000
Debt discount																																			3,000
Debt discount to be amortized																																			$ 32,000
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																			0.45
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																			240.83
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member]
Short-Term Debt [Line Items]
Debt discount																																		$ 3,700
Warrant term																																																							11 months 15 days
Deemed dividend																																	$ 11,000
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																	0.92
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																	247.52
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																																$ 1.50																		$ 1
Class of warrants | shares																																10,667																		25,333
Debt discount																																	$ 15,784
Debt discount to be amortized																																	$ 37,916
Warrant term																																6 months 25 days	7 months 6 days
Debt instrument, convertible, conversion price | $ / shares																																																		$ 1
Deemed dividend																																$ 25,000
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																0.81	0.48
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																209	302.11
Warrant [Member] | Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																																$ 1.90
Debt discount to be amortized																																$ 56,454
Warrant [Member] | Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																0.81
Warrant [Member] | Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																																253
Warrant [Member] | Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																															$ 1.90
Debt discount to be amortized																															$ 62,220
Debt issuance costs																															$ 30,000
Warrant [Member] | Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Debt conversion converted instrument rate																										24%
Warrants and rights outstanding measurement input																															0.77
Warrant [Member] | Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input																															254
Warrant [Member] | Convertible Promissory Note - October 4, 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																														$ 1.90
Warrant [Member] | Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																													$ 1.90
Warrant [Member] | Secured Convertible Promissory Note Two [Member]
Short-Term Debt [Line Items]
Debt discount																																											$ 407,000
Derivative liabilities																																									$ 972,000		972,000
Derivative expense																																											565,000
Loss on fair value of derivative liabilities																																											2,500,000
Change in the fair value of derivative liabilities																																											3,000,000
Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares	$ 0.036			$ 0.054	$ 0.054	$ 0.18	$ 0.279									$ 0.56
Securities Purchase Agreement [Member] | Secured Convertible Promissory Note - February 2020 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized																																							$ 21,000
Debt issuance costs																																							38,000
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount															$ 285,714																										350,000		350,000
Interest expense																																									6,800		11,400	0
Accured interest																																									11,400		11,400
Proceeds from issuance of secured debt															200,000
Proceeds from Convertible Debt															173,850
Payments of Debt Issuance Costs															26,150
Debt discount															203,000																										50,600		91,200	0
Debt discount to be amortized															85,700																										111,800		111,800
Debt issuance costs															$ 26,200
Warrant term															66 months
Warrants maturity date															Jul. 18, 2028
Warrant exercise price increase decrease | $ / shares															$ 0.82
Debt instrument, convertible, conversion price | $ / shares	0.036			0.054	0.054	$ 0.18	0.279
Debt instrument interest rate, effective percentage															30%
Debt interest amount, conversion of common stock, shares | shares															452,962
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | May 2022 [Member]
Short-Term Debt [Line Items]
Principal amount															$ 277,777
Interest rate, percentage															25%
Loan inducement fee																																											277,777
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | February 16 Term Loan [Member]
Short-Term Debt [Line Items]
Principal amount											$ 69,444
Interest rate, percentage											25%
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | April 28 Term Loan [Member]
Short-Term Debt [Line Items]
Principal amount						$ 461,904
Interest rate, percentage						30%
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | June 22 Term Loan [Member]
Short-Term Debt [Line Items]
Interest rate, percentage		125%
Debt description		The Notes contain customary restrictive covenants which apply for as long as at least 75% of the Notes remain outstanding, including covenants against incurring new indebtedness or liens, repurchasing shares of common stock or common stock equivalents, paying dividends or distributions on equity securities, and transactions with affiliates, subject to certain exceptions and limitations. In addition, the SPA imposes certain additional negative covenants and obligations on the Company, including a prohibition on filing a registration statement (other than on Form S-8) unless at least 30% of the Notes have been repaid as of such filing, a prohibition on incurring new indebtedness at any time while any Notes are outstanding, and a 90-day restriction against issuing shares of common stock or common stock equivalents, subject to certain exceptions and limitations.
Interest rate, reduced percentage		100%
Securities Purchase Agreement [Member] | February 3 Term Loan [Member]
Short-Term Debt [Line Items]
Principal amount												$ 267,857																													267,857		267,857
Debt issuance costs												16,100
Interest expense																																									5,500		8,900	0
Accured interest																																									8,900		8,900
Proceeds from issuance of secured debt												150,000
Proceeds from Convertible Debt												$ 133,900
Debt description												the 12-month anniversary of the original issuance date of the Notes, or February 3, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.
Debt discount												$ 224,000																													55,800		90,800	0
Debt discount to be amortized												64,300																													133,200		133,200
Debt issuance costs												$ 16,100
Warrant term												66 months
Warrants maturity date												Aug. 03, 2028
Warrant exercise price increase decrease | $ / shares												$ 0.82
Debt instrument, convertible, conversion price | $ / shares	0.036			0.054	0.054	$ 0.18	0.279
Debt instrument interest rate, effective percentage												30%
Debt interest amount, conversion of common stock, shares | shares												424,652
Loan inducement fee												$ 53,600
Securities Purchase Agreement [Member] | February 16 Term Loan [Member]
Short-Term Debt [Line Items]
Principal amount											$ 214,286																														278,571		278,571
Debt issuance costs											$ 16,150
Warrants exercise price per share | $ / shares											$ 0.82
Interest expense																																									5,300		7,400	0
Accured interest																																									7,400		7,400
Proceeds from issuance of secured debt											$ 150,000
Proceeds from Convertible Debt											$ 133,850
Debt description											The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12 month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest
Debt discount											$ 163,600																														40,800		60,500	0
Debt discount to be amortized		$ 45,000									64,200																														103,100		103,100
Debt issuance costs		61,800									$ 16,200
Warrant term											66 months
Warrants maturity date											Aug. 16, 2028
Debt instrument, convertible, conversion price | $ / shares	0.036			0.054	0.054	$ 0.18	0.279
Debt instrument interest rate, effective percentage											30%
Debt interest amount, conversion of common stock, shares | shares											339,722
Securities Purchase Agreement [Member] | April 28 Term Loan [Member]
Short-Term Debt [Line Items]
Principal amount						$ 285,714																																			285,714		285,714
Warrants exercise price per share | $ / shares						$ 0.82
Interest expense																																									5,800		5,800
Accured interest																																									5,800		5,800
Proceeds from issuance of secured debt						$ 200,000
Proceeds from Convertible Debt						$ 200,000
Debt description						the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12 month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any)
Debt discount						$ 166,400																																					29,200
Debt discount to be amortized						$ 85,700																																			137,200		137,200
Warrant term						66 months
Debt instrument, convertible, conversion price | $ / shares	0.036			0.054	0.054
Debt instrument interest rate, effective percentage						30%
Debt interest amount, conversion of common stock, shares | shares						452,964
Securities Purchase Agreement [Member] | June 22 Term Loan [Member]
Short-Term Debt [Line Items]
Principal amount		$ 150,000																																							150,000		150,000
Warrants exercise price per share | $ / shares		$ 0.05
Interest expense																																									3,100	0	3,100	0
Accured interest																																									3,100		3,100
Proceeds from issuance of secured debt		$ 105,000
Debt description		the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12 month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any).
Debt discount		$ 106,800																																							2,600		2,600
Debt discount to be amortized																																									104,000		104,000
Warrant term		66 months
Debt instrument, convertible, conversion price | $ / shares	0.036
Debt interest amount, conversion of common stock, shares | shares		3,000,000
Securities Purchase Agreement [Member] | Warrant [Member] | Issuance of Promissory Note [Member]
Short-Term Debt [Line Items]
Debt issuance costs															$ 91,100
Securities Purchase Agreement [Member] | Warrant [Member] | February 3 Term Loan [Member]
Short-Term Debt [Line Items]
Debt issuance costs												$ 90,000
Securities Purchase Agreement [Member] | Warrant [Member] | February 16 Term Loan [Member]
Short-Term Debt [Line Items]
Debt issuance costs											$ 83,200
Securities Purchase Agreement [Member] | Warrant [Member] | April 28 Term Loan [Member]
Short-Term Debt [Line Items]
Debt issuance costs						$ 80,700
Securities Purchase Agreement [Member] | Secured Convertible Promissory Note - February 2020 [Member]
Short-Term Debt [Line Items]
Debt discount																																							30,000
Secured Convertible Promissory Note - February 2020 [Member]
Short-Term Debt [Line Items]
Principal amount																																							$ 550,500
Interest rate, percentage																																							10%																		18%
Maturity date																																							Aug. 05, 2020
Debt discount to be amortized																																							$ 381,000
Warrant term																																							5 years
Debt instrument, convertible, conversion price | $ / shares																																						$ 10
Debt instrument interest rate, effective percentage																																							10%
Convertible notes payable current																																							$ 499,950
Weighted average percentage																																						70%
Debt conversion converted instrument rate																																						60%
Stock combinations | $ / shares																																						$ 1
Secured Convertible Promissory Note - February 2020 [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Interest expense related party																																									20,800	$ 20,800	45,100	45,800
Secured Convertible Promissory Note - February 2020 [Member] | February 2020 Convertible Note [Member]
Short-Term Debt [Line Items]
Principal amount																																									$ 457,359		$ 457,359
Interest rate, percentage																																									140%		140%
Debt payment Interest																																											$ 230,500
Convertible note premium description																																											The 40% premium will be recorded once a demand occurs.
Secured Convertible Promissory Note - February 2020 [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt issuance costs																																							53,000
Debt discount to be amortized																																							$ 322,000
Registration Rights Agreement [Member] | Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Debt interest amount, conversion of common stock, shares | shares																																5,000
Registration Rights Agreement [Member] | Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Debt interest amount, conversion of common stock, shares | shares																															5,000
Registration Rights Agreement [Member] | Convertible Promissory Note - October 4, 2021 [Member]
Short-Term Debt [Line Items]
Debt interest amount, conversion of common stock, shares | shares																														2,977
Registration Rights Agreement [Member] | Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Debt interest amount, conversion of common stock, shares | shares																													2,977
Debt conversion shares issued or options issued | shares																													2,632
Accredited Investors [Member] | Term Loan Subscription Agreements [Member]
Short-Term Debt [Line Items]
Principal amount																																															$ 5,700,000
Debt issuance costs																																															$ 707,000
Interest rate, percentage																																								12%
Debt instrument, interest during period																																								15%
Maturity date																																															Jun. 28, 2020
Public Offering Price Transaction in to Preferred Stock																		90%
Warrants exercise price per share | $ / shares																		$ 0.3
Interest expense																																											$ 212,300	422,300
Accured interest																																									$ 3,300,000		3,300,000
Repayments of debt																																											5,700,000
Debt payment Interest																																											3,300,000
Accredited Investors [Member] | Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Principal amount																	$ 142,857																								142,857		142,857
Interest expense																																									2,800		5,700	0
Accured interest																																									6,300		6,300
Original issue discount																	42,857
Proceeds from issuance of secured debt																	$ 100,000
Class of warrants | shares																	158,537
Proceeds from Convertible Debt																	$ 82,400
Payments of Debt Issuance Costs																	17,600
Debt discount																	111,523																								27,800		55,300	0
Debt discount to be amortized																	$ 42,857																								50,700		50,700
Warrant term																	66 months
Warrants maturity date																	Jun. 15, 2028
Warrant exercise price increase decrease | $ / shares																	$ 0.82
Debt instrument, convertible, conversion price | $ / shares	$ 0.036			$ 0.054	0.054	$ 0.18	$ 0.279									$ 0.56
Debt conversion converted instrument rate	60%			60%		60%	60%									60%								60%
Shares issued, price per share | $ / shares	$ 0.036			$ 0.054	$ 0.054	$ 0.18	$ 0.279									$ 0.56								$ 0.78
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt issuance costs																	$ 17,600
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt issuance costs																	$ 51,066
Holder [Member] | Term Loan Subscription Agreements [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares																		$ 1
Investors [Member] | Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Principal amount																						$ 2,222,222																			2,900,000		2,900,000
Interest expense																																									56,700		106,300	25,200
Accured interest																																									222,400		222,400
Original issue discount																						222,222
Proceeds from issuance of secured debt																						$ 2,000,000
Class of warrants | shares																						1,111,112
Number of shares issued | shares																						19,231
Proceeds from Convertible Debt																						$ 1,692,200
Payments of Debt Issuance Costs																						$ 307,800
Debt description																						(i) the 12-month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.
Debt discount																						$ 1,693,000																			185,500		603,000	$ 100,600
Debt discount to be amortized																						222,222
Debt issuance costs																						$ 307,800
Warrant term																						66 months
Warrants maturity date																						Nov. 11, 2027																										Nov. 11, 2023
Warrant exercise price increase decrease | $ / shares																						$ 0.80
Increase in outstanding principal amount																																									333,300		680,600
Investors [Member] | Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member]
Short-Term Debt [Line Items]
Increase in outstanding principal amount																																									64,300		64,300
Investors [Member] | Securities Purchase Agreement [Member] | February 16 Term Loan [Member]
Short-Term Debt [Line Items]
Increase in outstanding principal amount																																									$ 64,300		$ 64,300
Investors [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt issuance costs																						$ 11,820
Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt issuance costs																						$ 1,151,137

Licensing Agreements (Details N

Licensing Agreements (Details Narrative) - USD ($)		6 Months Ended
	Mar. 16, 2018	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties Due		$ 24,500		$ 24,500
Les Laboratories Servier License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for royalties		$ 0	$ 0
Sub-Licensing Agreement [Member] | Accrued Liabilities [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment agreement for license agreement	$ 200,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Related Party [Member] - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Other Liabilities		$ 4,000
Officers and Directors [Member]
Related Party Transaction [Line Items]
Due from related parties	$ 12,000	$ 26,000

Schedule of Stockholder_ Equity

Schedule of Stockholder’ Equity Note, Warrants or Rights (Details)	Jun. 30, 2023 shares
Warrant [Member]
Class of Stock [Line Items]
Warrant shares	65,544,841
Expiring in 2023	154,929
Expiring in 2024	2,170,241
Expiring in 2025	49,810,421
Expiring in 2026	7,469,299
Expiring in 2027 and after	5,939,950
Bridge Loan [Member]
Class of Stock [Line Items]
Warrant shares	5,939,950
Expiring in 2027 and after	5,939,950
Convertible Notes [Member]
Class of Stock [Line Items]
Warrant shares	59,433,025
Expiring in 2024	2,153,466
Expiring in 2025	49,810,259
Expiring in 2026	7,469,299
Other [Member]
Class of Stock [Line Items]
Warrant shares	17,441
Expiring in 2023	504
Expiring in 2024	16,775
Expiring in 2025	162
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares	154,425
Expiring in 2023	154,425

Schedule of Warrants (Details)

Schedule of Warrants (Details)	6 Months Ended
	Jun. 30, 2023 shares
Equity [Abstract]
Warrants, Beginning Balance	6,785,914
Issued as a result of price adjustments on convertible notes	12,487,902
Variable quantity of warrants related to the February 2020 note	43,121,004
Warrants issued with 2022 Bridge Note	4,670,301
Expirations	(1,520,280)
Warrants, Ending Balance	65,544,841

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative)															3 Months Ended				6 Months Ended
	Jun. 23, 2023 USD ($) $ / shares shares	May 30, 2023 USD ($) $ / shares shares	May 10, 2023 USD ($) $ / shares shares	May 10, 2023 USD ($) $ / shares shares	Apr. 28, 2023 USD ($) $ / shares shares	Apr. 14, 2023 USD ($) $ / shares shares	Jan. 10, 2023 USD ($) $ / shares shares	Jun. 27, 2022 USD ($)	May 17, 2022 USD ($) $ / shares shares	May 12, 2022 USD ($) shares	May 11, 2022 USD ($) shares	Mar. 15, 2022 USD ($) shares	Jan. 27, 2022 USD ($) $ / shares shares	Mar. 19, 2021 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($)	Jun. 30, 2022 USD ($) shares	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	May 17, 2023 shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2019 shares	Jul. 31, 2018 shares	Apr. 30, 2018 shares	Aug. 31, 2015 shares	Mar. 31, 2014 shares
Class of Stock [Line Items]
Preferred stock, shares authorized															100,000				100,000			100,000
Stated value per share | $ / shares															$ 0.01				$ 0.01			$ 0.01
Conversion rate per share | $ / shares															$ 0.006				$ 0.006			0.006
Deemed dividend | $															$ 26,000
Issuance of common stock with term loan | $															61,000	$ 5,000		$ 28,000
Loss on extinguishment of debt | $															$ 36,000		$ 210,000		$ 75,000	$ 215,000
Weighted average exercise price | $ / shares																						$ 19.60
Intrinsic value | $															$ 1,600,000				$ 1,600,000
Convertible Debt [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, amount | $	$ 5,697	$ 9,203	$ 6,001		$ 21,314	$ 10,000	$ 3,839
Debt instrument, convertible, conversion price | $ / shares	$ 0.036	$ 0.059	$ 0.054	$ 0.054	$ 0.18	$ 0.28	$ 0.56
Principal amount | $	$ 799	$ 756	$ 489	$ 489	$ 6,586		$ 1,661
February 2020 Convertible Note [Member]
Class of Stock [Line Items]
Debt interest amount, conversion of common stock, shares							17,861
Issuance of common stock with term loan | $							$ 3,839
Accrued interest | $							6,161
Loss on extinguishment of debt | $							$ 5,500
Senior Secured Convertible Promissory Note [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Debt instrument, convertible, conversion price | $ / shares															$ 0.036				$ 0.036
Banking Agreement [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues											19,231	10,000
Fair value | $											$ 11,820	$ 14,384
Convertible Note Investor [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues												2,500	12,721
Issuance of common stock with term loan | $													$ 9,500
Accrued interest | $													422
Debt Securities, Trading | $													28,000
Loss on extinguishment of debt | $													18,000
Derivative, Fair Value, Net | $													23,000
Gain on extinguishment of debt | $								$ 23,000
Extinguishment of Debt, Gain (Loss), Net of Tax | $													$ 5,000
Fair value | $												$ 3,596
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares															154,425				154,425
Series E Warrants [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, amount | $														$ 25,900
Debt interest amount, conversion of common stock, shares														25,900
Series E Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares														$ 10
Series E Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares														$ 1
Series E Preferred Stocks [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares							$ 0.56						$ 0.78
Conversion of shares									3,059
Accrued dividends | $									$ 5,100,000
Accrued dividends shares									2,035,306
Conversion rate per share | $ / shares									$ 10
Series E Preferred Stocks [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares							$ 0.56						0.78
Common Stock [Member]
Class of Stock [Line Items]
Debt interest amount, conversion of common stock, shares	120,000	170,000	120,000	120,000	155,000	35,716	17,861
Debt instrument, convertible, conversion price | $ / shares	$ 0.036		$ 0.054	$ 0.054	$ 0.18	$ 0.279
Issuance of common stock with term loan | $															$ 4,000
Stock repurchased during period, shares																	(5,954)
Common Stock [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Debt interest amount, conversion of common stock, shares	180,000
Debt instrument, convertible, conversion price | $ / shares	$ 0.039
Series F Warrants [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, amount | $														$ 25,900
Debt interest amount, conversion of common stock, shares														25,900
Series F Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares							$ 0.56						0.78	$ 10
Series F Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares														$ 1
Series F Preferred Stocks [Member]
Class of Stock [Line Items]
Conversion of shares									358
Accrued dividends | $									$ 541,000
Accrued dividends shares									233,127
Conversion rate per share | $ / shares									$ 10
Series F Preferred Stocks [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares							0.56						$ 0.78
Series F preferred and Accrued Dividend [Member]
Class of Stock [Line Items]
Conversion of shares									358
Accrued dividends | $									$ 543,000
Accrued dividends shares									233,127
Conversion rate per share | $ / shares									$ 10
Series E Preferred and Accrued Dividends [Member]
Class of Stock [Line Items]
Conversion rate per share | $ / shares							$ 0.56		$ 10
Commitment Fee [Member]
Class of Stock [Line Items]
Stock repurchased during period, shares										5,954
Commitment fee | $										$ 2,000
Warrant [Member]
Class of Stock [Line Items]
Warrant shares															65,544,841				65,544,841
Weighted average exercise price | $ / shares															$ 0.04				$ 0.04
Adjustable warrants															65,479,780				65,479,780
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock designated shares															1,000				1,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock designated shares															90,000				90,000
Series C convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized															1,200				1,200			1,200
Preferred stock designated shares																											1,200
Stated value per share | $ / shares															$ 0.01				$ 0.01			$ 0.01
Preferred stock liquidation preference per share | $															$ 510,000,000				$ 510,000,000			$ 510,000,000
Preferred stock, shares outstanding															100				100			100
Preferred stock shares issued															100				100			100
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized															220				220			220
Preferred stock designated shares																										220
Stated value per share | $ / shares															$ 0.01				$ 0.01			$ 0.01
Preferred stock liquidation preference per share | $															$ 12,000,000				$ 12,000,000			$ 12,000,000
Preferred stock, shares outstanding															40				40			40
Preferred stock shares issued															40				40			40
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized															3,500				3,500			3,500
Preferred stock designated shares																									3,500
Stated value per share | $ / shares															$ 0.01				$ 0.01			$ 0.01
Preferred stock, shares outstanding															267				267			267
Preferred stock shares issued															267				267			267
Series F Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized															2,200				2,200			2,200
Preferred stock designated shares																								2,200
Stated value per share | $ / shares															$ 0.01				$ 0.01			$ 0.01
Preferred stock, shares outstanding															0				0			0
Preferred stock shares issued															0				0			0
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized															6,000				6,000			6,000
Preferred stock designated shares																							6,000
Stated value per share | $ / shares															$ 0.01				$ 0.01			$ 0.01
Preferred stock, shares outstanding															0				0			0
Preferred stock shares issued															0				0			0
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares															$ 5,000				$ 5,000
Preferred stock liquidation preference per share | $															$ 5,100				$ 5,100
Preferred Stock, Voting Rights																			voting rights of 33.33 votes per
Common stock at a conversion price, per share | $ / shares															$ 150				$ 150
Preferred stock, shares outstanding															100				100
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares															$ 5,000				$ 5,000
Preferred stock liquidation preference per share | $															$ 300				$ 300
Preferred Stock, Voting Rights																			voting rights of 62.5 votes per
Common stock at a conversion price, per share | $ / shares															$ 80				$ 80
Preferred stock, shares outstanding															40				40
Preferred stock stated dividend rate																			5%
Series E Convertible Preferred Stock and Warrants [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares															$ 5,000				$ 5,000
Common stock at a conversion price, per share | $ / shares															$ 10				$ 10
Preferred stock stated dividend rate																			8%
Antidilution price protection																Feb. 10, 2020
Series E Preferred Stocks [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding															267				267
Accrued dividends | $															$ 525,000				$ 525,000
Warrant shares																					1,453,028
Series F Convertible Preferred Stock and Warrants [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares															$ 5,000				$ 5,000
Common stock at a conversion price, per share | $ / shares															$ 10				$ 10
Preferred stock stated dividend rate																			8%
Antidilution price protection																			Feb. 10, 2020
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares															154,425				154,425
Deemed dividend | $														$ 31,000
Series F Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs														0.16
Series F Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs														262.27
Series F Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant term														6 months 10 days
Series F Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant term														5 months 15 days
Series G Convertible Preferred Shares [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares															$ 5,000				$ 5,000
Common stock at a conversion price, per share | $ / shares															$ 10				$ 10
Preferred stock stated dividend rate																			8%
Series G Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares issued															0				0			0

Schedule of Share Based Payment

Schedule of Share Based Payments Arrangement, Option Activity (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Options Outstanding Beginning | shares	19,000
Options Outstanding, Weighted Average Exercise Price, Beginning | $ / shares	$ 19.60
Options expired / forfeited | shares	(19,000)
Options expired/forfeited, Weighted Average Exercise Price | $ / shares	$ 19.60
Options Outstanding Ending | shares
Options Outstanding, Weighted Average Exercise Price, Ending | $ / shares
Options Exercisable | shares
Exercisable, Weighted Average Exercise Price | $ / shares

Stock Incentive Plans (Details

Stock Incentive Plans (Details Narrative)	6 Months Ended
	Jun. 30, 2023 shares
Share-Based Payment Arrangement [Abstract]
Shares granted	0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)								1 Months Ended
	Feb. 01, 2023	Jul. 20, 2022	Jul. 18, 2022	Nov. 17, 2021	Aug. 20, 2021	Aug. 20, 2021	Jul. 28, 2021	Feb. 16, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement commitments description				On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, if by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising.
Licensing Agreement MLR1019 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment							$ 21,800,000
Gross sales percentage							5%
Option purchase percentage							10%
Royalty gross sales percentage							2.50%
Licensing Agreement - MLR 1023 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement commitments description				On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising	On August 20, 2021, the Company as licensee, entered into an exclusive license agreement regarding the development and commercialization of Melior’s MLR-1023 (the “MLR-1023 Agreement”) with Melior Pharmaceuticals I, Inc. (“MP1”). The Company refers to MP2 and MP1 as “MP” or “Melior”. This second license is for the development and commercialization of MLR-1023, which is being developed as a novel therapeutic for Type 1 diabetes.	if the Company failed to raise $4.0 million within 120 days of the effective date of the agreement then the MLR-1023 Agreement would immediately terminate unless, by 120 days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 days would be provided to allow for the completion of the raise (the “Raise Requirement”).		he Company to raise $4 million (the “Raise Requirement”) to June 16, 2022.
Licensing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for licensing agreement		$ 136,921	$ 136,921
Capital raise in additional	$ 500,000	$ 500,000	500,000
Licensing Agreement [Member] | Chief Scientific Officer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Capital raise in additional			$ 500,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Aug. 10, 2023	Jul. 27, 2023	Jun. 23, 2023	May 30, 2023	May 10, 2023	May 10, 2023	Apr. 28, 2023	Apr. 14, 2023	Jan. 10, 2023
Common Stock [Member]
Subsequent Event [Line Items]
Debt instrument, convertible, conversion price			$ 0.036		$ 0.054	$ 0.054	$ 0.18	$ 0.279
Debt interest amount, conversion of common stock, shares			120,000	170,000	120,000	120,000	155,000	35,716	17,861
Convertible Debt [Member]
Subsequent Event [Line Items]
Debt conversion, converted instrument, amount			$ 5,697	$ 9,203		$ 6,001	$ 21,314	$ 10,000	$ 3,839
Principal amount			$ 799	$ 756	$ 489	$ 489	$ 6,586		$ 1,661
Debt instrument, convertible, conversion price			$ 0.036	$ 0.059	$ 0.054	$ 0.054	$ 0.18	$ 0.28	$ 0.56
Convertible Debt [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Debt instrument, convertible, conversion price			$ 0.039
Debt interest amount, conversion of common stock, shares			180,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Debt interest amount, conversion of common stock, shares	196,085	187,966
Subsequent Event [Member] | Convertible Debt [Member]
Subsequent Event [Line Items]
Debt conversion, converted instrument, amount	$ 2,000	$ 2,250
Principal amount	$ 734	$ 805
Debt instrument, convertible, conversion price	$ 0.013	$ 0.016